VANGUARD Ethics Workshop
March 18, 2022
Bio-artificial organs and bio-engineered or bio-printed tissues for transplantation in humans are rapidly being developed. It is anticipated that some applications will be ready for
New Generation Cell Therapy:
Bioartificial Pancreas to Cure Type 1 Diabetes
Why needed?
Forty million individuals worldwide suffer from type 1 diabetes. This disease is managed by insulin therapy in a vast majority of patients because of the limited accessibility of beta cell replacement therapies.
There is an urgent need for the development of a beta cell replacement therapy that will be available to larger numbers of type 1 diabetic patients.
Our solution
The VANGUARD project aims to generate a vascularized and immune-protected bioartificial pancreas that can be transplanted into non-immuno-suppressed patients by combining advanced tissue engineering strategies.
This approach will yield a cell therapy in the form of an Advanced Therapy Medicinal Product (ATMP), which can significantly improve treatment of type 1 diabetes.
Project overview
News
New publication on the generation of pre-vascularised organoids
January 24, 2022
The VANGUARD consortium recently published collaborative work in the journal Transplant International on the generation of pre-vascularised organoids. The authors from the University of Geneva
Registration is open for the VANGUARD workshop on ethics in regenerative medicine
January 12, 2022
Online workshop on the topic of bio-artificial organs and bio-engineered or bio-printed tissues for transplantation in humans that are rapidly being developed.